A Phase 3 interventional study of Maraviroc in Acquired Immunodeficiency Syndrome and HIV Infection, sponsored by ViiV Healthcare. Completed at 16 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-09-09.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing maraviroc in Acquired Immunodeficiency Syndrome — 2 open to participants now, 2 under way, none of them phase 3. Maraviroc · Acquired Immunodeficiency Syndrome.
Among the 29 studies testing maraviroc in Acquired Immunodeficiency Syndrome, this one is the 6th largest by enrollment, is the only one that started in 2007, is one of 6 in phase 3, and was the 2nd registered.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →2 of the 29 studies testing maraviroc in Acquired Immunodeficiency Syndrome are open now, in 2 countries. Recruiting first, the newest first:
Federal University of São Paulo · Sites in Brazil
Ages 18–65
National Cancer Institute (NCI) · Sites in United States
Ages 12–120 · Healthy volunteers
By country, each count listing its studies:
Maraviroc: first FDA approval 2007 (SELZENTRY), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 198 Acquired Immunodeficiency Syndrome studies recruiting now, 118 (60%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 4 · Phase 3 7 · Phase 4 11
First in 2004; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 209 is above the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Median enrollment 31 across the 29 interventional studies. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
207 studies in Acquired Immunodeficiency Syndrome by GlaxoSmithKline: 6 open now, 11 under way, 4 of them phase 3. Of 188 finished, 67 (36%) have results posted.
Among the 207 studies in Acquired Immunodeficiency Syndrome by GlaxoSmithKline, this one is the 31st largest by enrollment of the 172 interventional ones that give a count, is one of 6 that started in 2007, is one of 33 in phase 3, and was the 40th registered.
GlaxoSmithKline’s Acquired Immunodeficiency Syndrome studies by the year they started, since 2001.
2 of the studies testing maraviroc in Acquired Immunodeficiency Syndrome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06805656Federal University of São PauloMulti Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals | 2027-03-01 |
| NCT05470491National Cancer Institute (NCI)Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... | 2027-07-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing maraviroc in Acquired Immunodeficiency Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 207 in Acquired Immunodeficiency Syndrome:
This tab as a report to print or save as PDF → With an account.
To collect safety and tolerability data in a more diverse patient population of patients with HIV/Aids, who have limited therapeutic options.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Maraviroc
Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)
AEs: any untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was congenital anomaly. Grade 3: Events that interrupted participant's usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4: Events which were unacceptable and intolerable or which were irreversible or caused participant to be in imminent danger of death.
Time frame: Baseline to 30 days post-week 96 or early termination (ET)
Number of Participants With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 and Grade 4 Laboratory Abnormalities
Grade 3 or severe events included those that interrupted participant's usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 or very severe events included those that were unacceptable and intolerable or which were irreversible or caused the participant to be in imminent danger of death.
Time frame: Baseline to 30 days post-week 96 or ET
Number of Participants With Treatment Emergent Malignancies
Time frame: Baseline to 30 days post-week 96 or ET
Number of Participants With Category C Acquired Immunodeficiency Syndrome (AIDS) Related Infections
Number of participants with AIDS-related infections based on investigator classification guided by a predefined list of clinical Category C AEs per Center for Disease Control (CDC) HIV Classification System.
Time frame: Baseline to 30 days post-week 96 or ET
Number of Participants With Laboratory Test Abnormalities
Pre-defined criteria based on upper limit normal (ULN) and lower limit normal (LLN) were established for each laboratory test to define the values that would be identified as laboratory test abnormality.
Time frame: Baseline to 30 days post-week 96 or ET
Percentage of Participants With at Least 0.5 Log 10 Reduction in Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA)
Time frame: Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or end of treatment (EOT)
Percentage of Participants With at Least 1.0 Log 10 Reduction in HIV-1 RNA
Time frame: Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Percentage of Participants Achieving HIV-1 RNA Below Limit of Quantification
Below limit of quantification was defined as less than 400 copies/milliliter (mL)
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Change From Baseline in CD4 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Change From Baseline in CD8 Percent at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Number of Participants With C-X-C Chemokine Receptor Type 4 {CXCR4} [X4] Tropism Status
Virus tropism was done by the Monogram Biosciences Trofile assay.
Time frame: Time of virologic failure (VF) and Week 96 or EOT
Change From Baseline in Human Immunodeficiency Virus (HIV) -1 Viral Load (Ribonucleic Acid [RNA]) at Week 4, 8, 12, 24, 36, 48, 60, 72, 84 and Week 96 or EOT
Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log 10 copies per milliliter \[log10 copies/ml\]).
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36, Week 48, Week 60, Week 72, Week 84 and Week 96 or EOT
Time to Virologic Failure (VF)
Virologic failure was defined as failing to achieve a reduction in HIV-1 RNA of at least 0.5 log10 copies/ml from baseline by the second viral load determination; or experiencing at least 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline more than 0.5 log10 copies/ml; or experiencing an HIV-1 RNA more than 1000 copies/ml after having achieved an HIV-1 RNA below level of quantification.
Time frame: Baseline to Week 96 or EOT
Number of Participants With Genotype Resistance
Evolution in resistance to OBT was shown by emergence of new primary or secondary resistance mutations to nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI).
Time frame: Baseline through Week 96
| Milestone | Maraviroc |
|---|---|
| Started | 209 |
| Treated | 206 |
| Completed | 125 |
| Not completed | 84 |
| Withdrew: Death | 7 |
| Withdrew: Lack of efficacy | 47 |
| Withdrew: Lost to follow-up | 7 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Other | 9 |
| Withdrew: Adverse event | 5 |
| Withdrew: Randomized, not treated | 3 |
AEs: any untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was congenital anomaly. Grade 3: Events that interrupted participant's usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4: Events which were unacceptable and intolerable or which were irreversible or caused participant to be in imminent danger of death.
| Participants | Maraviroc |
|---|---|
| Grade 3 AEs | 40 |
| Grade 4 AEs | 9 |
| SAEs | 34 |
Grade 3 or severe events included those that interrupted participant's usual daily activity and traditionally required systemic drug therapy or other treatment. Grade 4 or very severe events included those that were unacceptable and intolerable or which were irreversible or caused the participant to be in imminent danger of death.
| Participants | Maraviroc |
|---|---|
| Grade 3: Alanine aminotransferase (ALT) | 0 |
| Grade 3: Aspartate aminotransferase (AST) | 4 |
| Grade 3: Absolute neutrophil count (ANC) | 7 |
| Grade 3: Alkaline phosphatase | 1 |
| Grade 3: Gamma-glutamyl transpeptidase (GGT) | 15 |
| Grade 3: Hyperbilirubinemia | 17 |
| Grade 3: Hyperuricemia | 3 |
| Grade 3: Lipase (n= 101) | 8 |
| Grade 3: Platelets | 3 |
| Grade 3: Potassium (Hyperkalemia) | 0 |
| Grade 3: Serum amylase | 12 |
| Grade 4: Alanine aminotransferase (ALT) | 1 |
| Grade 4: Aspartate aminotransferase (AST) | 0 |
| Grade 4: Absolute neutrophil count (ANC) | 4 |
| Grade 4: Alkaline phosphatase | 0 |
| Grade 4: Gamma-glutamyl transpeptidase (GGT) | 8 |
| Grade 4: Hyperbilirubinemia | 6 |
| Grade 4: Hyperuricemia | 1 |
| Grade 4: Lipase (n= 101) | 2 |
| Grade 4: Platelets | 0 |
| Grade 4: Potassium (Hyperkalemia) | 2 |
| Grade 4: Serum amylase | 1 |
| Participants | Maraviroc |
|---|---|
| Carcinoma in situ | 1 |
| Hodgkin's disease | 1 |
| Intestinal T-cell lymphoma | 1 |
| Neoplasm of appendix | 1 |
Number of participants with AIDS-related infections based on investigator classification guided by a predefined list of clinical Category C AEs per Center for Disease Control (CDC) HIV Classification System.
| Participants | Maraviroc |
|---|---|
| Cerebral toxoplasmosis | 2 |
| Disseminated cryptococcosis | 1 |
| Oesophageal candidiasis | 3 |
| Pneumocystis jiroveci pneumonia | 3 |
| Leukoencephalopathy | 1 |
Pre-defined criteria based on upper limit normal (ULN) and lower limit normal (LLN) were established for each laboratory test to define the values that would be identified as laboratory test abnormality.
| Participants | Maraviroc |
|---|---|
| Hematocrit (<0.8*LLN) | 13 |
| Red blood cell count (<0.8*LLN) | 35 |
| White blood cell count (<0.6*LLN) | 7 |
| White blood cell count (>1.5*ULN) | 4 |
| Absolute lymphocytes (<0.8*LLN) | 12 |
| Absolute lymphocytes (>1.2*ULN) | 60 |
| Percent lymphocytes (<0.8*LLN) (n= 1) | 0 |
| Percent lymphocytes (>1.2*ULN) (n= 1) | 1 |
| Percent neutrophils (<0.8*LLN) (n= 1) | 1 |
| Percent neutrophils (>1.2*ULN) (n= 1) | 0 |
| Absolute basophils (>1.2*ULN) | 10 |
| Percent basophils (>1.2*ULN) (n= 1) | 0 |
| Absolute eosinophils (>1.2*ULN) | 32 |
| Percent eosinophils (>1.2*ULN) (n= 1) | 0 |
| Absolute monocytes (>1.2*ULN) | 25 |
| Percent monocytes (>1.2*ULN) (n= 1) | 0 |
| Direct Bilirubin (>1.5*ULN) | 67 |
| Indirect bilirubin (>1.5*ULN) | 25 |
| Lactose dehydrogenase (LDH) (>3.0*ULN) | 1 |
| Total protein (<0.8*LLN) | 1 |
| Total protein (>1.2*ULN) | 19 |
| Albumin (<0.8*LLN) | 3 |
| Albumin (>1.2*ULN) | 0 |
| Blood urea nitrogen (BUN) (>1.3*ULN) | 7 |
| Cholesterol (>1.3*ULN) | 26 |
| High density lipoprotein cholesterol (<0.8*LLN) | 115 |
| Low density lipoprotein cholesterol (>1.2*ULN) | 101 |
| Triglycerides (>1.3*ULN) | 145 |
| Calcium (<0.9*LLN) | 6 |
| Calcium (>1.1*ULN) | 0 |
| Creatine kinase (CK) (>2.0*ULN) | 50 |
| Percentage of participants | Maraviroc |
|---|---|
| Week 4 (n= 202) | 78.7 |
| Week 8 (n= 196) | 78.6 |
| Week 12 (n= 190) | 80.5 |
| Week 24 (n= 185) | 79.5 |
| Week 36 (n= 171) | 83.6 |
| Week 48 (n= 158) | 82.3 |
| Week 60 (n= 141) | 84.4 |
| Week 72 (n= 137) | 81.0 |
| Week 84 (n= 125) | 82.4 |
| Week 96 or EOT (n= 109) | 89.9 |
| LOCF (n= 206) | 76.2 |
| Percentage of participants | Maraviroc |
|---|---|
| Week 4 (n= 202) | 67.8 |
| Week 8 (n= 196) | 68.9 |
| Week 12 (n= 190) | 71.1 |
| Week 24 (n= 185) | 68.6 |
| Week 36 (n= 171) | 69.0 |
| Week 48 (n= 158) | 70.3 |
| Week 60 (n= 141) | 70.2 |
| Week 72 (n= 137) | 64.2 |
| Week 84 (n= 125) | 71.2 |
| Week 96 or EOT (n= 109) | 72.5 |
| LOCF (n= 206) | 61.2 |
Below limit of quantification was defined as less than 400 copies/milliliter (mL)
| Percentage of participants | Maraviroc |
|---|---|
| Baseline | 2.4 |
| Week 4 (n= 202) | 29.7 |
| Week 8 (n= 196) | 43.9 |
| Week 12 (n= 190) | 42.6 |
| Week 24 (n= 185) | 41.1 |
| Week 36 (n= 171) | 47.4 |
| Week 48 (n= 158) | 41.1 |
| Week 60 (n= 141) | 36.2 |
| Week 72 (n= 137) | 24.8 |
| Week 84 (n= 125) | 23.2 |
| Week 96 or EOT (n= 109) | 33.9 |
| LOCF (n= 206) | 26.7 |
| cells per microliter (cells/µL) | Maraviroc |
|---|---|
| Baseline | 215.6 ± 179.9 |
| Change at Week 4 (n= 190) | 93.5 ± 96.7 |
| Change at Week 8 (n= 190) | 110.0 ± 95.2 |
| Change at Week 12 (n= 186) | 132.1 ± 164.1 |
| Change at Week 24 (n= 184) | 137.3 ± 115.0 |
| Change at Week 36 (n= 165) | 157.8 ± 128.4 |
| Change at Week 48 (n= 154) | 172.2 ± 124.0 |
| Change at Week 60 (n= 134) | 187.2 ± 140.4 |
| Change at Week 72 (n= 129) | 199.8 ± 161.0 |
| Change at Week 84 (n= 124) | 198.2 ± 177.3 |
| Change at Week 96 or EOT (n= 107) | 225.2 ± 175.3 |
| Change at LOCF (n= 201) | 174.1 ± 168.5 |
| cells/µL | Maraviroc |
|---|---|
| Baseline | 1016.4 ± 676.3 |
| Change at Week 4 (n= 190) | 387.3 ± 597.0 |
| Change at Week 8 (n= 190) | 518.3 ± 666.4 |
| Change at Week 12 (n= 186) | 507.2 ± 685.6 |
| Change at Week 24 (n= 185) | 358.1 ± 577.2 |
| Change at Week 36 (n= 165) | 352.3 ± 545.3 |
| Change at Week 48 (n= 155) | 348.6 ± 591.0 |
| Change at Week 60 (n= 135) | 349.1 ± 566.7 |
| Change at Week 72 (n= 130) | 272.4 ± 594.8 |
| Change at Week 84 (n= 124) | 246.7 ± 567.3 |
| Change at Week 96 or EOT (n= 107) | 214.5 ± 593.2 |
| Change at LOCF (n= 201) | 223.0 ± 562.0 |
| Percent CD4 | Maraviroc |
|---|---|
| Baseline | 12.2 ± 7.5 |
| Change at Week 4 (n= 190) | 1.8 ± 3.4 |
| Change at Week 8 (n= 190) | 1.3 ± 3.2 |
| Change at Week 12 (n= 186) | 2.1 ± 4.4 |
| Change at Week 24 (n= 184) | 2.9 ± 3.7 |
| Change at Week 36 (n= 165) | 3.6 ± 3.9 |
| Change at Week 48 (n= 154) | 4.3 ± 4.1 |
| Change at Week 60 (n= 134) | 4.5 ± 4.5 |
| Change at Week 72 (n= 129) | 5.2 ± 4.3 |
| Change at Week 84 (n= 124) | 5.3 ± 5.2 |
| Change at Week 96 or EOT (n= 107) | 6.6 ± 5.1 |
| Change at LOCF (n= 201) | 4.9 ± 5.3 |
| Percent CD8 | Maraviroc |
|---|---|
| Baseline | 59.8 ± 13.1 |
| Change at Week 4 (n= 190) | 0.4 ± 6.1 |
| Change at Week 8 (n= 190) | 0.9 ± 7.3 |
| Change at Week 12 (n= 186) | -0.1 ± 8.2 |
| Change at Week 24 (n= 185) | -2.5 ± 8.3 |
| Change at Week 36 (n= 165) | -3.6 ± 8.6 |
| Change at Week 48 (n= 155) | -4.3 ± 9.9 |
| Change at Week 60 (n= 135) | -4.7 ± 10.4 |
| Change at Week 72 (n= 130) | -6.1 ± 10.9 |
| Change at Week 84 (n= 124) | -6.8 ± 10.3 |
| Change at Week 96 or EOT (n= 107) | -7.7 ± 10.7 |
| Change at LOCF (n= 201) | -5.4 ± 10.6 |
Virus tropism was done by the Monogram Biosciences Trofile assay.
| Participants | Maraviroc |
|---|---|
| VF X4 (n= 134) | 7 |
| EOT X4 (n= 146) | 8 |
Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log 10 copies per milliliter \[log10 copies/ml\]).
| log 10 copies/ml | Maraviroc |
|---|---|
| Baseline | 4.8 ± 0.9 |
| Change at week 4 (n= 202) | -1.5 ± 1.0 |
| Change at week 8 (n= 196) | -1.5 ± 1.1 |
| Change at week 12 (n= 190) | -1.6 ± 1.1 |
| Change at week 24 (n= 185) | -1.6 ± 1.1 |
| Change at week 36 (n= 171) | -1.6 ± 1.0 |
| Change at week 48 (n= 158) | -1.6 ± 1.0 |
| Change at week 60 (n= 141) | -1.6 ± 1.1 |
| Change at week 72 (n= 137) | -1.4 ± 1.1 |
| Change at week 84 (n= 125) | -1.5 ± 1.1 |
| Change at week 96 or EOT (n= 109) | -1.7 ± 1.0 |
| Change at LOCF (n= 206) | -1.4 ± 1.1 |
Virologic failure was defined as failing to achieve a reduction in HIV-1 RNA of at least 0.5 log10 copies/ml from baseline by the second viral load determination; or experiencing at least 0.5 log10 increase from nadir in HIV-1 RNA after achieving an HIV-1 RNA reduction from baseline more than 0.5 log10 copies/ml; or experiencing an HIV-1 RNA more than 1000 copies/ml after having achieved an HIV-1 RNA below level of quantification.
| Days | Maraviroc |
|---|---|
| Time to Virologic Failure (VF) | 255.0 (172.0 to 336.0) |
Evolution in resistance to OBT was shown by emergence of new primary or secondary resistance mutations to nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI).
| Participants | Maraviroc |
|---|---|
| VF: NRTI | 0 |
| VF: NNRTI | 0 |
| VF: PI | 16 |
| VF: NRTI and NNRTI | 0 |
| VF: NRTI and PI | 32 |
| VF: NNRTI and PI | 7 |
| VF: NRTI and NNRTI and PI | 64 |
| VF: no NRTI, no NNRTI and no PI | 0 |
| VF: no test result data | 48 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maraviroc | — | 34/206 (16.5%) | 185/206 (89.8%) |
| Event | Maraviroc |
|---|---|
| SepsisInfections and infestations | 4/206 |
| PyrexiaGeneral disorders | 3/206 |
| PneumoniaInfections and infestations | 3/206 |
| ConvulsionNervous system disorders | 3/206 |
| Abdominal painGastrointestinal disorders | 2/206 |
| DiarrhoeaGastrointestinal disorders | 2/206 |
| VomitingGastrointestinal disorders | 2/206 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/206 |
| AnaemiaBlood and lymphatic system disorders | 1/206 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/206 |
| Event | Maraviroc |
|---|---|
| DiarrhoeaGastrointestinal disorders | 33/206 |
| NasopharyngitisInfections and infestations | 32/206 |
| HeadacheNervous system disorders | 22/206 |
| Subcutaneous noduleSkin and subcutaneous tissue disorders | 22/206 |
| SinusitisInfections and infestations | 18/206 |
| NauseaGastrointestinal disorders | 17/206 |
| Upper respiratory tract infectionInfections and infestations | 17/206 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 17/206 |
| RashSkin and subcutaneous tissue disorders | 15/206 |
| VomitingGastrointestinal disorders | 14/206 |
| Age Continuous(Years) | Maraviroc |
|---|---|
| Mean | 43.2 ± 7.6 |
| Sex: Female, Male(Participants) | Maraviroc |
|---|---|
| Female | 61 |
| Male | 145 |
The record gives a start of Jul 2007, a primary completion of Aug 2010 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maraviroc
Acquired Immunodeficiency Syndrome →